Vinge has advised the international private equity firm PSG Equity in connection with its investment in Visit Group International AB ("Visit Group")

Headquartered in Gothenburg, Sweden, Visit Group is a market leader in the Nordics within hospitality and travel technology, providing collaborative commerce software to in-destination experience vendors, including lodgings, day tours and attractions, mountain resorts, ferry operators, amusement parks and activity vendors. As of August 2023, the company serves more than 2,200 customers in over 25 countries. Visit Group’s multiple software solutions create a unique ecosystem that helps hospitality and travel providers package, sell, distribute, and deliver guest experiences.

PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 130+ companies and facilitated over 470+ add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams.

With PSG’s support, Visit Group will invest to help accelerate both organic and inorganic growth across the region by broadening the range and depth of solutions offered to its customers. The transaction marks PSG’s first platform investment in Sweden and Norway.

Vinges team mainly consisted of Christina Kokko, Samra Tesser, Gustav Wahlberg and Jonatan Stentorp (M&A), Axel Lennartsson (IP), Gulestan Ali (Employment), Martin Boström (Agreements), Carla Zachariasson (IT), Arthur Kinski (GDPR), Maja Höglund (Compliance), Karl-Gustaw Tobola and August Ahlin (Financing), Frida Ställborn (Real Property) as well as Emma Emsjö and Johanna Engström (Transaction Support Coordinators).

Related

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of their production facility in Uppsala to Ofichem. The Uppsala site specializes in small-scale, early-phase development work.
August 13, 2025

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025